Xiaofei Zhou

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Jonathan W. Friedberg, Daruka Mahadevan, Erin Cebula et al. · Journal of Clinical Oncology · 2013 · 209 citations · Full text

Medicine, Hematology, Pharmacology +17

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Ursula A. Matulonis, Sudarshan Sharma, Michael S. Gordon et al. · Gynecologic Oncology · 2012 · 134 citations

Medicine, Oncology, Pharmacology +16

Electrochemical Sizing of Organic Nanoparticles

Wei Cheng, Xiaofei Zhou, Richard G. Compton · Angewandte Chemie International Edition · 2013 · 104 citations

Natural Sciences, Chemistry, Materials Science +12

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer

Gerald S. Falchook, Robert L. Coleman, A. Roszak et al. · JAMA Oncology · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Kevin R. Kelly, Thomas C. Shea, André Goy et al. · Investigational New Drugs · 2013 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17